H.C. Wainwright initiated coverage on Celularity with a new price target
$CELU
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $5.00 → $1.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 6/22/2022 | $15.00 | Buy | H.C. Wainwright |
| 4/6/2022 | $10.00 | Buy → Hold | Truist |
| 1/28/2022 | $9.00 | Outperform | Oppenheimer |
| 11/24/2021 | $9.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $12.00 | Buy | Truist Securities |
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
10-Q - Celularity Inc (0001752828) (Filer)
Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously
Oppenheimer downgraded Celularity from Outperform to Perform
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera
FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi
FLORHAM PARK, N.J., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it has received a letter from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq"), confirming that Celularity has regained compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"). Following the filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2024, Nasdaq has determined that the matter is now closed. "We are pleased to have fully addressed Nasdaq's requirements and resolved this matter, ensuring that our stock remains listed and continues to trade
Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023 FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings. For the nine months
FLORHAM PARK, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that on November 21, 2024, the Company received notification from the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company does not comply with the Nasdaq continued listing requirements due to the Company's inability to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the "Q3 Form 10-Q"). Nasdaq's notice has no immediate effect on the listing of Celularity's co